Election Law - Absentee Ballots - Signature Requirements and Verification
House Bill 830 requires certain Maryland health insurers, nonprofit health service plans, and health maintenance organizations to cover specified genetic testing and follow-up cancer imaging for individuals with a personal or family history of cancer who may have an inherited mutation associated with increased cancer risk. Coverage is limited to testing and imaging that are recommended by a health care professional and consistent with evidence-based clinical practice guidelines, including National Comprehensive Cancer Network oncology guidelines for follow-up imaging.
The bill also prohibits these carriers from imposing copayments, coinsurance, or deductibles on the covered genetic testing and follow-up imaging, with limited exceptions for high-deductible health plans under federal health savings account rules. The law applies to policies, contracts, and health benefit plans issued, delivered, or renewed in Maryland on or after January 1, 2026.
HB0830 adds a new section to Maryland’s Insurance Article requiring coverage of certain cancer-related genetic testing and evidence-based imaging and restricting cost-sharing for those services. It affects insurers, nonprofit health service plans, and HMOs that provide hospital, medical, or surgical benefits in the state, and it creates a new mandated benefit for qualifying individuals at increased hereditary cancer risk. The bill also interacts with federal HSA-qualified high-deductible health plan rules by preserving deductible treatment where required under federal law.
The available legislative record suggests the bill moved forward favorably in the House, with the committee reporting it favorably with amendments and the House adopting it on second reading. That procedural history indicates generally positive support for expanding access to preventive cancer-related services. No committee transcript or recorded vote details were provided, so the record does not show any formal opposition in the materials supplied.
The main policy issue is the cost and scope of mandated insurance coverage. Support is implicit in the bill’s focus on removing financial barriers to genetic testing and follow-up imaging for people with a personal or family history of cancer, while potential concerns for insurers and plan sponsors would center on premium impact, utilization, and administrative complexity. A narrower point of contention is the bill’s interaction with federal high-deductible health plan and health savings account requirements, which requires special treatment to avoid disqualifying certain plans.